Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus

被引：28
作者：
Chatzidionysiou, Katerina [1 ]
Samoli, Evangelia [2 ]
Sfikakis, Petros P. [1 ]
Tektonidou, Maria G. [1 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Dept Propaedeut & Internal Med 1, Joint Rheumatol Program, Laiko Hosp,Med Sch, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens, Greece
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷 / 02期
关键词：
D O I：
10.1136/annrheumdis-2019-216367
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：304 / +
页数：4
相关论文
共 10 条
[1]  
[Anonymous], 2019, ANN RHEUM DIS
[2]   Hydroxychloroquine Use Is Associated with Lower Odds of Persistently Positive Antiphospholipid Antibodies and/or Lupus Anticoagulant in Systemic Lupus Erythematosus [J].
Broder, Anna ;
Putterman, Chaim .
JOURNAL OF RHEUMATOLOGY, 2013, 40 (01) :30-33
[3]   Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus [J].
Cavazzana, I ;
Kumar, R. ;
Pozzari, C. ;
Ottaviani, R. ;
Fredi, M. ;
Piantom, S. ;
Andreoli, L. ;
Tincani, A. ;
Franceschini, F. .
LUPUS, 2019, 28 (09) :1074-1081
[4]   Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment [J].
Emmi, Giacomo ;
Bettiol, Alessandra ;
Palterer, Boaz ;
Silvestri, Elena ;
Vitiello, Gianfranco ;
Parronchi, Paola ;
Prisco, Domenico .
AUTOIMMUNITY REVIEWS, 2019, 18 (03) :312-314
[5]   FLUCTUATIONS OF ANTICARDIOLIPIN ANTIBODY-LEVELS IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS - A PROSPECTIVE-STUDY [J].
OUT, HJ ;
DEGROOT, PG ;
HASSELAAR, P ;
VANVLIET, M ;
DERKSEN, RHWM .
ANNALS OF THE RHEUMATIC DISEASES, 1989, 48 (12) :1023-1028
[6]   A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases [J].
Ramos-Casals, Manuel ;
Brito-Zeron, Pilar ;
Munoz, Sandra ;
Soto, Maria-Jose .
MEDICINE, 2008, 87 (06) :345-364
[7]   Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome [J].
Rodriguez-Pinto, Ignasi ;
Cervera, Ricard ;
Espinosa, Gerard .
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2015, 7 (01) :26-30
[8]   Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab [J].
Sciascia, Savino ;
Rubini, Elena ;
Radin, Massimo ;
Cecchi, Irene ;
Rossi, Daniela ;
Roccatello, Dario .
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (11) :1693-+
[9]   Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus [J].
Stohl, William ;
Hiepe, Falk ;
Latinis, Kevin M. ;
Thomas, Mathew ;
Scheinberg, Morton A. ;
Clarke, Ann ;
Aranow, Cynthia ;
Wellborne, Frank R. ;
Abud-Mendoza, Carlos ;
Hough, Douglas R. ;
Pineda, Lilia ;
Migone, Thi-Sau ;
Zhong, Z. John ;
Freimuth, William W. ;
Chatham, W. Winn .
ARTHRITIS AND RHEUMATISM, 2012, 64 (07) :2328-2337
[10]   Belimumab in primary antiphospholipid syndrome [J].
Yazici, A. ;
Yazirli, B. ;
Erkan, D. .
LUPUS, 2017, 26 (10) :1123-1124
1